Overview

A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Darifenacin